Table 1.

Reference rituximab doses and consumption for induction and maintenance treatment in various indications

Diagnosis	Induction dose	Maintenance dose	Total RTX consumption per patient (mg)
RA	–	2 × 1000 mg/6 months	4000.00
DLBCL	375 mg/m2 per cycle, for up to 8 cycles	–	5370.00
FL
Newly diagnosed	375 mg/m2 per cycle, for up to 8 cycles	375 mg/m2 every 2 months (starting 2 months after the last dose of induction therapy), until disease progression or for a maximum period of 2 years	1814.00
Relapsed/refractory	375 mg/m2 per cycle, for up to 8 cycles	375 mg/m2 once every 3 months (starting 3 months after the last dose of induction therapy), until disease progression or for a maximum period of 2 years	1933.20
CLL	–	1 × 375 mg/m2 + 5 × 500 mg/m2	5146.25

Mean body surface area was set at 1.79 m² according to a retrospective analysis of over 3500 patients receiving chemotherapy treatment at three oncology centers in the UK [54]

CLL chronic lymphocytic leukemia, DLBCL diffuse large B cell lymphoma, FL follicular lymphoma, RA rheumatoid arthritis, RTX reference rituximab